Cancer antibodies that can advance your immunooncology therapeutics pipelines

Cancer: the world’s common enemy—it’s fascinating, perplexing, and devastating. Since the development of the first chemotherapies in the late 1940s, cancer therapeutics R&D has shifted towards a more targeted approach. For instance, cancer immunotherapy is one modern treatment paradigm giving hope to people around the world. Blockade of immune checkpoint proteins, such as CTLA-4 and PD-1/PD-L1 and blockade of cancer cell migration are among the most promising therapeutic approaches for cancer treatment. To identify suitable cancer-driving targets and effectively block them in your milestone in vitro and in vivo studies, you need cancer antibodies you can rely on.

Bio X Cell offers a wide selection of antibodies against cancer-related targets and biomarkers. Our antibodies are highly pure with extremely low endotoxin levels and no preservatives or stabilizers added making them ideal for highly sensitive in vivo and in vitro experiments.

These antibodies span a large variety of antigens including immune checkpoint ligands and receptors, co-stimulatory proteins, cytokines and cytokine receptors, and adhesion proteins. For a more focused lists of antibodies and cancer research related products see the immune checkpoint protein and cell migration and adhesion product categories.